Currently an oral RAD51 inhibitor CYT-0851 is being tested in a Phase 1/2 study against relapsed/refractory B-cell malignancies and advanced solid tumours including breast cancer (NCT03997968). This evidence concerns the gene RAD51 and breast cancer.